| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Department of Pharmacy (Dr. Abi-Nassif and Mr. Hallisey), the Department of Medicine (Dr. Fogel), Division of Pulmonary and Critical Care, and the Department of Pathology (Dr. Mark), Massachusetts General Hospital, Boston, MA.
Correspondence to: Sandra Abi-Nassif, PharmD, Attending Pharmacist, Department of Pharmacy, MGH, Room GRB 005, 55 Fruit St, Boston, MA 02114; e-mail: sabinassif{at}partners.org
 |
Abstract |
|---|
 TOP Abstract IntroductionCase ReportDiscussionReferences |
|---|
2b in combination with ribavirin. He developed ARDS and died after 26 days of hospitalization from multisystem organ failure. This case suggests that interstitial pulmonary disease can occur with pegylated interferon-2b therapy.
Key Words: ARDS • interferon- • interstitial lung disease
|
Introduction |
|---|
|
TOPAbstractIntroductionCase ReportDiscussionReferences |
|---|
is the mainstay of hepatitis C virus (HCV) treatment. Due to the high frequency of relapse seen with conventional interferon therapy, other treatment options have been explored, namely, pegylated interferon-2b, used alone or in combination with ribavirin.
Pegylated interferon-2b has various side effects. Interstitial pneumonitis has been previously described as a complication of interferon- therapy1
2
3
4
5
6
but, to our knowledge, never has been reported with pegylated interferon-2b therapy following its approval by the US Food and Drug Administration in January 2001. We describe here a patient who developed interstitial pneumonitis with ARDS following two weekly doses of pegylated interferon-2b in combination with ribavirin therapy.
|
Case Report |
|---|
|
TOPAbstractIntroductionCase ReportDiscussionReferences |
|---|
The patient was started on a combination treatment consisting of pegylated interferon-2b and ribavirin. He weighed 94 kg. Both medications were appropriately prescribed (pegylated interferon-2b, 150 µg once weekly; and ribavirin, 600 mg bid).
Two weeks after the initiation of treatment, the patient presented to the emergency department of an outside hospital with cough and dyspnea. On hospital admission, a chest radiograph revealed bilateral interstitial and alveolar infiltrates that were greater on the right than on the left (Fig 1
). Oxyhemoglobin saturation dropped from 93 to 87% while breathing room air, and the patient was consequently given oxygen therapy using a nasal cannula. A possible pulmonary allergic reaction to pegylated interferon-2b was suspected as the cause of his symptoms, and the patient therefore was started on therapy with methylprednisolone, 60 mg IV q8h. Therapy with levofloxacin, 500 mg po qd, also was initiated to cover for possible community-acquired pneumonia. On day 3 of hospital admission, the patient awoke with increased shortness of breath. His oxyhemoglobin saturation was 80% despite a 100% oxygen concentration being administered by face mask. Arterial blood gas levels were as follows: PO2, 73 mm Hg; PCO2, 42 mm Hg; and pH 7.44. The findings of the cardiac examination were normal, and the echocardiogram showed a normal left ventricular ejection fraction and no other evidence of congestive heart failure.
|
|
On day 11, an open lung biopsy was performed. Histopathologically, the lung showed diffuse alveolar damage from acute interstitial pneumonitis with progression to interstitial fibrosis. Active disease was manifested as interstitial widening by proliferating fibroblasts and myxoid connective tissue, as well as by the presence of lymphocytes in the walls of the alveoli (Fig 3 ). The alveoli contained fibrin. Pneumocytes in areas of active fibrosis were hyperplastic. Other regions of the lung showed distorted and remodeled alveolar architecture and rounded alveoli due to the diffuse interstitial inflammation and fibrosis (Fig 4 ). The interstitial pneumonitis was determined histologically to be of a few weeks’ duration. No significant old lung disease was present. No granulomas were present. No eosinophils were present. No organisms were detected by stain or culture.
|
|
On day 24, the patient underwent a total colectomy, cholecystectomy, and ileostomy for acalculus cholecystitis and for removal of a potential abdominal source of sepsis. The exploratory laparotomy with cholangiogram showed ascites, a cirrhotic liver, an inflamed distended gallbladder, and no evidence of cholangitis. On day 25, the patient developed severe metabolic acidosis with worsening renal function requiring continuous venovenous hemofiltration. His condition deteriorated rapidly with worsening ARDS and multisystem organ failure, despite maximal life-sustaining therapy. At that time, LFTs revealed an AST level of 1,408 U/L and an ALT level of 2,195 U/L. Arterial blood gas levels when the patient had a 100% fraction of inspired oxygen were as follows: PCO2, 57 mm Hg; PO2, 47 mm Hg; and pH 7.17. On day 26, blood culture results came back positive for methicillin-resistant Staphylococcus aureus and Candida albicans. Sputum culture results also were positive for methicillin-resistant S aureus. The patient died on day 26, and an autopsy was performed.
The lungs together weighed 3,200 g, which is five times the normal weight. They showed diffuse alveolar damage in a more advanced fibrosing state. There was also evidence of necrotizing bronchopneumonia, acute tubular necrosis, and micronodular cirrhosis with extensive ischemic hepatic necrosis.
|
Discussion |
|---|
|
TOPAbstractIntroductionCase ReportDiscussionReferences |
|---|
2b was approved by the US Food and Drug Administration in 2001 for the treatment of patients with chronic HCV who have compensated liver disease. The use of this agent has resulted in a significantly higher sustained virologic response than the one seen with conventional interferon-2b therapy.8 Pegylation is the attachment of an inactive, nontoxic polyethylene glycol moiety to the active conventional interferon molecule. The resulting compound has sustained absorption, considerably higher serum concentration, a slower rate of clearance, and a longer half-life, allowing for more constant therapeutic concentrations.
The biological activity of pegylated interferon is derived from the interferon- moiety. Interferons bind to specific membrane receptors on the cell surface, and trigger a cascade of intracellular events and immunomodulating activities. These include the induction of enzymes, the suppression of cell proliferation, the enhancement of macrophage phagocytic activity, and the augmentation of the specific cytotoxicity of lymphocytes for target cells.9
Pegylated interferon has various side effects, including inflammation at the injection site, the triggering of autoimmune diseases, dyspnea, and cough, with influenza-like symptoms being the most commonly reported.8
9
10
Pulmonary infiltrates and pneumonitis with pegylated interferon- have been reported only during premarketing studies.9
Ribavirin is a synthetic nucleoside analog that appears to enhance the anti-HCV activity of both conventional interferon- and pegylated interferon-, leading to a higher sustained virologic response.8
11
12
To this date, ribavirin alone has never been reported as the cause for interstitial pneumonitis.
The lack of significant improvement despite antibiotic therapy, and negative findings on BAL specimen studies, blood cultures, and viral antibody tests are consistent with a noninfectious process. The pathology findings for a lung biopsy sample are one way of discovering the presence of pulmonary disease that may be related to drugs.13 The histology is unusual in that hyaline membranes that are characteristic of diffuse alveolar damage were not present. However, fibroblast infiltrates, hyperplastic pneumocytes, and a thrombosed blood vessel were present, as is commonly seen in diffuse alveolar damage.
Moreover, we know that medications can be a possible etiology of ARDS. Aspirin, opiates, tricyclic antidepressants, carbamazepine, amiodarone, protamine, radiologic contrast media, and certain antineoplastic agents have been reported to precipitate this syndrome.14 15 16 17 18 19 20 21 22 Therefore, since the patient experienced ARDS, one cannot exclude pegylated interferon from the potential etiologies.
Severe pulmonary toxicity from therapy with interferon-2b and pegylated interferon-2b is rare (1 to 5%).9
23
But with increased prescribing for various clinical conditions (eg, neoplasms, multiple sclerosis, and HCV), there is growing evidence for interferon-–induced pulmonary toxicities, which have been captured in a number of case reports, as follows: pneumonitis1
2
3
4
5
6
; sarcoidosis24
25
26
27
; asthma exacerbation28
; pleural effusion29
; and bronchiolitis obliterans-organizing pneumonia.30
Although the mechanism of interferon-–induced pulmonary toxicity has never been clearly defined, the immunomodulating activities of this agent are one plausible explanation. However, as suggested in previous reports,5
27
31
32
this reaction may be due to an immune-mediated response in the lungs, with pegylated interferon, acting as an immunostimulant, triggering underlying but quiescent autoimmune disease in this patient. This mechanism has been reported previously33
34
35
to be associated with thyroid disease in patients who have been treated with interferon-.
Pharmacokinetic studies comparing conventional interferon-2b to pegylated interferon-2b have shown that the mean area under the curve and the mean duration of measurable serum concentration following a single dose of 0.5 µg/kg pegylated interferon-2b are 13 times and 11 times greater, respectively, than the one observed with a dose of 3 million IU conventional interferon-2b. These findings are the expected results of pegylation. However, it remains speculative whether these findings are linked to an increased toxicity of pegylated interferon-2b and its rapid onset in this patient.
In clinical trials,8
10
11
the reported incidence of dyspnea and cough in patients who have been treated with pegylated interferon- combination therapy with ribavirin was higher than the one observed with interferon- monotherapy. However, whether ribavirin was a synergistic cause of the development of interstitial pneumonitis in this patient remains theoretical.
Although the clinical and pathologic findings suggest that the interstitial pneumonitis in this patient may have been caused by pegylated interferon/ribavirin therapy, one cannot prove that a definite causal relationship actually exists, as this is only a single case report. We believe, however, that the patient’s course and lack of other etiologies for ARDS make the relationship between interferon and ARDS suggestive.
We believe that the immediate cause of death for this patient was sepsis and multisystem organ failure. However, because these occurred as complications of pegylated interferon-2b–induced lung disease, this patient’s death should be considered a drug-related mortality.
Since interferon-2b is the active moiety in pegylated interferon-2b, interstitial pneumonitis is also likely to occur with this newer agent. Patients receiving pegylated interferon-2b monotherapy or combination therapy with ribavirin should be made aware of this complication and should be advised to watch for pulmonary symptoms. In the instance in which these symptoms occur, pegylated interferon-2b/ribavirin-induced interstitial pneumonitis should be considered in the differential diagnosis and therapy must be withheld.
While this manuscript was being reviewed for submission, a case of interstitial pneumonitis induced by pegylated interferon-2a and ribavirin therapy was reported.36
|
Footnotes |
|---|
This research was supported by the Pharmacy Department at Massachusetts General Hospital.
Received for publication June 14, 2002. Accepted for publication January 30, 2003.
|
References |
|---|
|
TOPAbstractIntroductionCase ReportDiscussionReferences |
|---|
therapy associated with the development of sarcoidosis. Chest 1999;116,569-572[Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
